Franklin Resources Inc Exelixis, Inc. Transaction History

Franklin Resources Inc

  • $313 Billion
  • Q2 2024

A detailed history of Franklin Resources Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 867,441 shares of EXEL stock, worth $31.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
867,441
Previous 862,224 0.61%
Holding current value
$31.1 Million
Previous $20.5 Million 4.74%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$20.34 - $23.73 $106,113 - $123,799
5,217 Added 0.61%
867,441 $19.5 Million
Q1 2024

May 13, 2024
BUY
$20.17 - $23.93 $8.63 Million - $10.2 Million
427,753 Added 98.45%
862,224 $20.5 Million
Q4 2023

Feb 09, 2024
BUY
$19.25 - $24.13 $1.6 Million - $2 Million
82,916 Added 23.59%
434,471 $10.4 Million
Q3 2023

Nov 13, 2023
BUY
$19.04 - $22.74 $4.27 Million - $5.09 Million
224,005 Added 175.62%
351,555 $7.68 Million
Q2 2023

Aug 11, 2023
BUY
$18.17 - $20.48 $579,459 - $653,127
31,891 Added 33.34%
127,550 $2.44 Million
Q1 2023

May 12, 2023
SELL
$16.3 - $19.41 $121,418 - $144,585
-7,449 Reduced 7.22%
95,659 $1.86 Million
Q4 2022

Feb 10, 2023
SELL
$14.96 - $17.39 $2.21 Million - $2.56 Million
-147,493 Reduced 58.86%
103,108 $1.65 Million
Q3 2022

Nov 14, 2022
BUY
$15.68 - $22.27 $3.68 Million - $5.23 Million
234,652 Added 1471.26%
250,601 $3.93 Million
Q2 2022

Aug 11, 2022
SELL
$17.44 - $23.16 $173,929 - $230,974
-9,973 Reduced 38.47%
15,949 $331,000
Q1 2022

May 13, 2022
SELL
$17.03 - $22.67 $78,610 - $104,644
-4,616 Reduced 15.12%
25,922 $589,000
Q4 2021

Feb 11, 2022
BUY
$15.84 - $21.88 $9,218 - $12,734
582 Added 1.94%
30,538 $558,000
Q3 2021

Nov 12, 2021
SELL
$16.3 - $21.14 $138,501 - $179,626
-8,497 Reduced 22.1%
29,956 $634,000
Q2 2021

Aug 13, 2021
SELL
$17.95 - $25.56 $1.23 Million - $1.76 Million
-68,721 Reduced 64.12%
38,453 $700,000
Q1 2021

May 13, 2021
SELL
$20.53 - $25.22 $170,891 - $209,931
-8,324 Reduced 7.21%
107,174 $2.42 Million
Q4 2020

Feb 10, 2021
SELL
$18.39 - $24.8 $953,098 - $1.29 Million
-51,827 Reduced 30.97%
115,498 $2.32 Million
Q3 2020

Nov 12, 2020
SELL
$20.67 - $26.94 $231,855 - $302,185
-11,217 Reduced 6.28%
167,325 $4.09 Million
Q2 2020

Aug 13, 2020
SELL
$16.46 - $27.42 $78,431 - $130,656
-4,765 Reduced 2.6%
178,542 $4.44 Million
Q1 2020

May 13, 2020
BUY
$14.46 - $21.8 $284,081 - $428,282
19,646 Added 12.0%
183,307 $3.16 Million
Q4 2019

Feb 12, 2020
BUY
$15.15 - $18.89 $554,050 - $690,826
36,571 Added 28.78%
163,661 $2.88 Million
Q3 2019

Nov 14, 2019
BUY
$17.68 - $22.65 $705,750 - $904,142
39,918 Added 45.79%
127,090 $2.25 Million
Q2 2019

Aug 14, 2019
BUY
$18.93 - $24.75 $572,613 - $748,662
30,249 Added 53.14%
87,172 $1.86 Million
Q1 2019

May 14, 2019
SELL
$19.6 - $24.76 $13.8 Million - $17.4 Million
-701,583 Reduced 92.5%
56,923 $1.35 Million
Q4 2018

Feb 12, 2019
SELL
$13.65 - $21.8 $17.2 Million - $27.5 Million
-1,261,134 Reduced 62.44%
758,506 $14.9 Million
Q3 2018

Nov 13, 2018
SELL
$15.87 - $22.4 $3.02 Million - $4.27 Million
-190,510 Reduced 8.62%
2,019,640 $35.8 Million
Q2 2018

Aug 14, 2018
BUY
$18.56 - $22.45 $1.4 Million - $1.69 Million
75,209 Added 3.52%
2,210,150 $47.6 Million
Q1 2018

May 10, 2018
SELL
$22.15 - $31.89 $5.1 Million - $7.35 Million
-230,330 Reduced 9.74%
2,134,941 $47.3 Million
Q4 2017

Feb 14, 2018
SELL
$24.23 - $30.93 $3.55 Million - $4.53 Million
-146,529 Reduced 5.83%
2,365,271 $71.9 Million
Q3 2017

Nov 13, 2017
BUY
$23.35 - $29.24 $58.7 Million - $73.4 Million
2,511,800
2,511,800 $60.9 Million

Others Institutions Holding EXEL

# of Institutions
465
Shares Held
240M
Call Options Held
1.87M
Put Options Held
1.12M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Franklin Resources Inc Portfolio

Follow Franklin Resources Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email